During the last session, Puma Biotechnology Inc (NASDAQ:PBYI)’s traded shares were 0.84 million, with the beta value of the company hitting 1.08. At the end of the trading day, the stock’s price was $2.95, reflecting an intraday loss of -5.45% or -$0.17. The 52-week high for the PBYI share is $7.73, that puts it down -162.03 from that peak though still a striking 24.75% gain since the share price plummeted to a 52-week low of $2.22. The company’s market capitalization is $144.81M, and the average intraday trading volume over the past 10 days was 0.59 million shares, and the average trade volume was 446.03K shares over the past three months.
Puma Biotechnology Inc (PBYI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. PBYI has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
Puma Biotechnology Inc (NASDAQ:PBYI) trade information
Puma Biotechnology Inc (PBYI) registered a -5.45% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.45% in intraday trading to $2.95, hitting a weekly high. The stock’s 5-day price performance is -6.35%, and it has moved by -9.79% in 30 days. Based on these gigs, the overall price performance for the year is -32.80%. The short interest in Puma Biotechnology Inc (NASDAQ:PBYI) is 2.91 million shares and it means that shorts have 5.73 day(s) to cover.
Puma Biotechnology Inc (PBYI) estimates and forecasts
Statistics show that Puma Biotechnology Inc has underperformed its competitors in share price, compared to the industry in which it operates.
While earnings are projected to return -33.33% in 2025.
PBYI Dividends
Puma Biotechnology Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Puma Biotechnology Inc (NASDAQ:PBYI)’s Major holders
Puma Biotechnology Inc insiders own 15.14% of total outstanding shares while institutional holders control 67.74%, with the float percentage being 79.82%. VANGUARD GROUP INC is the largest shareholder of the company, while 138.0 institutions own stock in it. As of 2024-06-30, the company held over 3.6 million shares (or 7.4684% of all shares), a total value of $11.73 million in shares.
The next largest institutional holding, with 3.57 million shares, is of BLACKROCK INC.’s that is approximately 7.4141% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $11.65 million.
